VRTX in the 13F filings
Vertex Pharmaceuticals Inc · CUSIP 92532F100
- Quarter end
- 30 Jun 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 25 Jul 2024
- Managers listing it
- 29
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q1 2024 and Q2 2024; 26 listed it in both
- Shares listed
- 71,348,442
- combined, among listed positions
- Reported value
- $33.4bn
- combined, at the quarter end
Among the 94 comparable managers: 12 buyers (opened or added shares) and 18 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing VRTX in Q2 2024
29 of 29 holders
Largest increases and reductions, by shares
Increases
- Capital Research Global Investorsexisting position · 8,539,339 shares now+2,795,457
- Capital World Investorsexisting position · 26,707,966 shares now+1,140,782
- Baillie Gifford & Conew position · 167,616 shares now+167,616
- Hudson Bay Capital Management LPnew position · 137,500 shares now+137,500
- AllianceBernstein LPexisting position · 7,221,072 shares now+123,791
Reductions
- T. Rowe Price Associates Incexisting position · 2,211,674 shares now-2,281,748
- Wellington Management Group LLPexisting position · 4,094,449 shares now-463,784
- Man Group PLCexisting position · 197,296 shares now-330,628
- Invesco Ltdexisting position · 1,802,742 shares now-288,401
- D. E. Shaw & Co.existing position · 170,063 shares now-185,395
New positions and exits
New (2)
Exited (2)
- ExodusPoint Capital Management LPwas $22m
- Tudor Investment Corpwas $9.8m
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 13 | $5.0bn | n.a. | n.a. |
| Q3 2013 | 12 | $4.6bn | n.a. | n.a. |
| Q4 2013 | 9 | $4.8bn | n.a. | n.a. |
| Q1 2014 | 11 | $4.9bn | n.a. | n.a. |
| Q2 2014 | 11 | $7.3bn | n.a. | n.a. |
| Q3 2014 | 14 | $9.0bn | n.a. | n.a. |
| Q4 2014 | 15 | $9.3bn | n.a. | n.a. |
| Q1 2015 | 21 | $9.2bn | n.a. | n.a. |
| Q2 2015 | 23 | $9.4bn | n.a. | n.a. |
| Q3 2015 | 22 | $8.3bn | n.a. | n.a. |
| Q4 2015 | 19 | $10.2bn | n.a. | n.a. |
| Q1 2016 | 18 | $6.8bn | n.a. | n.a. |
| Q2 2016 | 13 | $7.5bn | n.a. | n.a. |
| Q3 2016 | 14 | $7.7bn | n.a. | n.a. |
| Q4 2016 | 14 | $6.3bn | n.a. | n.a. |
| Q1 2017 | 21 | $9.5bn | n.a. | n.a. |
| Q2 2017 | 24 | $11.0bn | n.a. | n.a. |
| Q3 2017 | 28 | $12.6bn | n.a. | n.a. |
| Q4 2017 | 24 | $12.2bn | n.a. | n.a. |
| Q1 2018 | 24 | $13.3bn | n.a. | n.a. |
| Q2 2018 | 27 | $14.0bn | n.a. | n.a. |
| Q3 2018 | 26 | $15.7bn | n.a. | n.a. |
| Q4 2018 | 27 | $14.6bn | n.a. | n.a. |
| Q1 2019 | 26 | $17.0bn | n.a. | n.a. |
| Q2 2019 | 24 | $17.0bn | n.a. | n.a. |
| Q3 2019 | 25 | $16.0bn | n.a. | n.a. |
| Q4 2019 | 29 | $20.0bn | n.a. | n.a. |
| Q1 2020 | 27 | $20.9bn | n.a. | n.a. |
| Q2 2020 | 27 | $23.4bn | n.a. | n.a. |
| Q3 2020 | 31 | $21.9bn | n.a. | n.a. |
| Q4 2020 | 30 | $18.4bn | n.a. | n.a. |
| Q1 2021 | 31 | $15.4bn | n.a. | n.a. |
| Q2 2021 | 30 | $12.7bn | n.a. | n.a. |
| Q3 2021 | 35 | $10.1bn | n.a. | n.a. |
| Q4 2021 | 28 | $12.4bn | n.a. | n.a. |
| Q1 2022 | 23 | $16.1bn | n.a. | n.a. |
| Q2 2022 | 25 | $18.1bn | n.a. | n.a. |
| Q3 2022 | 22 | $18.4bn | n.a. | n.a. |
| Q4 2022 | 28 | $18.4bn | n.a. | n.a. |
| Q1 2023 | 26 | $21.4bn | n.a. | n.a. |
| Q2 2023 | 27 | $24.7bn | n.a. | n.a. |
| Q3 2023 | 33 | $24.3bn | n.a. | n.a. |
| Q4 2023 | 32 | $28.6bn | 16 | 16 |
| Q1 2024 | 31 | $29.8bn | 16 | 19 |
| Q2 2024 | 29 | $33.4bn | 12 | 18 |
| Q3 2024 | 27 | $33.5bn | 17 | 10 |
| Q4 2024 | 26 | $28.5bn | 14 | 13 |
| Q1 2025 | 21 | $35.4bn | 10 | 11 |
| Q2 2025 | 21 | $32.3bn | 11 | 11 |
| Q3 2025 | 22 | $25.9bn | 13 | 10 |
| Q4 2025 | 26 | $31.8bn | 19 | 20 |
| Q1 2026 | 25 | $31.8bn | 17 | 21 |
| Q2 2026 | 26 | $34.6bn | 21 | 17 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
VRTX and LLY →VRTX and JNJ →VRTX and GILD →Choose a stock to compare with VRTX →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own VRTX, latest filings →Back to the 13F Explorer →